Production and functional characteristics of a novel hirudin variant with better anticoagulant activities than bivalirudin
Basic science / preclinical published in J Enzyme Inhib Med Chem (2025)
Abstract
Current antithrombotic therapies face dual constraints of bleeding complications and monitoring requirements. Although natural hirudin provides targeted thrombin inhibition, its clinical adoption is hindered by sourcing limitations. This study developed a recombinant hirudin variant HMg (rHMg) with enhanced anticoagulant activity through genetic engineering and established cost-effective large-scale production methods. The synthesised HMg gene was expressed in E. coli BL21 via a pET vector plasmid, followed by nickel-affinity purification. Systematic evaluations demonstrated rHMg's antithrombin activity of 9573 ATU/mg, dose-dependent prolongation of APTT/PT/TT. It has superior thrombin inhibition with the IC50 and Ki values were 2.8 and 0.323 nM respectively compared to FDA approved drug bivalirudin (p < 0.001). The high-yield prokaryotic expression of rHMg with enhanced anticoagulant efficacy provides a novel strategy for developing affordable antithrombotic drugs, showing significant potential for cardiovascular disease management.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Genetic engineering of a recombinant hirudin variant (rHMg) expressed in E. coli, with antithrombin activity of 9573 ATU/mg and IC50/Ki superior to bivalirudin. Demonstrates a path to next-generation hirudin-based anticoagulants.
Why This Matters for Hirudotherapy
This laboratory study engineered a recombinant variant of leech-derived hirudin (rHMg) in E. coli and reports an antithrombin activity of 9573 ATU/mg, dose-dependent prolongation of APTT/PT/TT, and IC50/Ki values (2.8 and 0.323 nM) the authors describe as superior to the FDA-approved direct thrombin inhibitor bivalirudin (p<0.001). For hirudotherapy this sits squarely in the leech-secretome drug-discovery story: hirudin, the medicinal leech's signature thrombin inhibitor, remains the molecular template for an entire class of anticoagulants, and the work targets the long-standing bottleneck of natural sourcing through scalable prokaryotic production. The honest caveat is that these are preclinical, in-vitro enzymatic and coagulation-assay results in a recombinant peptide; no human dosing, safety, or efficacy is demonstrated, and 'better activity than bivalirudin' here means enzyme-kinetic potency, not a clinical outcome.
Citation
Production and functional characteristics of a novel hirudin variant with better anticoagulant activities than bivalirudin.
Ge P et al. · Journal of enzyme inhibition and medicinal chemistry, 2025
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026